| scholarly article | Q13442814 |
| P50 | author | Gang G Wang | Q80521785 |
| Deyou Zheng | Q37390105 | ||
| P2093 | author name string | Masoud Vedadi | |
| Benjamin A Garcia | |||
| Fengling Li | |||
| Ying Liu | |||
| Shichong Liu | |||
| Stephen V Frye | |||
| Jian Jin | |||
| Ling Cai | |||
| Samantha G Pattenden | |||
| Shira Rockowitz | |||
| Anqi Ma | |||
| Bowen Xu | |||
| David F Allison | |||
| Doan M On | |||
| Kyle D Konze | |||
| Trevor Parton | |||
| P2860 | cites work | Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia | Q40130350 |
| Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. | Q40219637 | ||
| Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. | Q41872521 | ||
| Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer | Q41942526 | ||
| A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia | Q42053261 | ||
| Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. | Q43832946 | ||
| NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. | Q46277256 | ||
| Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. | Q50594569 | ||
| Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. | Q50803016 | ||
| Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. | Q54341375 | ||
| A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis | Q57261238 | ||
| Ezh1 Is Required for Hematopoietic Stem Cell Maintenance and Prevents Senescence-like Cell Cycle Arrest | Q60033499 | ||
| Switching on epigenetic therapy | Q82223266 | ||
| Selective inhibition of BET bromodomains | Q24301009 | ||
| An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting | Q24307370 | ||
| Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers | Q24605342 | ||
| EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency | Q24645960 | ||
| Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger | Q27655436 | ||
| Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations | Q27681082 | ||
| Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain | Q27681087 | ||
| Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin | Q27851546 | ||
| The language of covalent histone modifications | Q27860931 | ||
| Histone methylation: a dynamic mark in health, disease and inheritance | Q28263573 | ||
| Distinct factors control histone variant H3.3 localization at specific genomic regions | Q28275277 | ||
| The Polycomb complex PRC2 and its mark in life | Q29547358 | ||
| Cancer epigenetics: from mechanism to therapy | Q29614799 | ||
| MLL translocations, histone modifications and leukaemia stem-cell development | Q29615368 | ||
| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | Q29615392 | ||
| Cancer epigenomics: DNA methylomes and histone-modification maps | Q29615524 | ||
| Epigenetic protein families: a new frontier for drug discovery | Q29616621 | ||
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 | ||
| Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. | Q33716402 | ||
| Quantitative mass spectrometry of histones H3.2 and H3.3 in Suz12-deficient mouse embryonic stem cells reveals distinct, dynamic post-translational modifications at Lys-27 and Lys-36 | Q33854968 | ||
| The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. | Q33915185 | ||
| Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines | Q33951701 | ||
| Examining histone posttranslational modification patterns by high-resolution mass spectrometry | Q33978003 | ||
| Chromatin immunoprecipitation and microarray-based analysis of protein location | Q34003310 | ||
| DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. | Q34017960 | ||
| The role of mutations in epigenetic regulators in myeloid malignancies | Q34033164 | ||
| Chromatin proteins and modifications as drug targets | Q34038652 | ||
| Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes | Q34080062 | ||
| A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells | Q34302726 | ||
| Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation | Q34317380 | ||
| An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1 | Q34341058 | ||
| Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas | Q34397318 | ||
| Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells | Q34619655 | ||
| Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth | Q35030824 | ||
| Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. | Q35051547 | ||
| Polycomb repressive complex 2 is required for MLL-AF9 leukemia | Q35882496 | ||
| Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms | Q36810306 | ||
| Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. | Q36835530 | ||
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation | Q36926825 | ||
| The molecular biology of mixed lineage leukemia | Q37522825 | ||
| Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma | Q39021479 | ||
| DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells | Q39112529 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P1104 | number of pages | 12 | |
| P304 | page(s) | 346-357 | |
| P577 | publication date | 2014-11-13 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia | |
| P478 | volume | 125 |
| Q92523612 | A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3AR882) Demonstrates a Causal Relationship between Its Dominant-Negative Effect and Leukemogenesis |
| Q42140535 | A Transcription Factor Pulse Can Prime Chromatin for Heritable Transcriptional Memory |
| Q33626131 | A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination |
| Q36432056 | Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a |
| Q28069695 | Advances in sarcoma diagnostics and treatment |
| Q90394240 | Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma |
| Q36201086 | An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition |
| Q101166870 | BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis |
| Q26799462 | Biological features and biomarkers in hepatocellular carcinoma |
| Q53689778 | C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. |
| Q38540375 | Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology |
| Q36067075 | Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response |
| Q42687340 | Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. |
| Q91826942 | Discovery of a first-in-class EZH2 selective degrader |
| Q38876767 | Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains |
| Q42776492 | Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition |
| Q48649399 | Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia |
| Q57806363 | Dual inhibition of EZH1/2 over-activates WNT signaling to deplete cancer stem cells in multiple myeloma |
| Q92487157 | Dual roles of EZH2 in acute myeloid leukemia |
| Q28082054 | EZH2 in Bladder Cancer, a Promising Therapeutic Target |
| Q91756439 | EZH2 inhibition suppresses bladder cancer cell growth and metastasis via the JAK2/STAT3 signaling pathway |
| Q38844652 | EZH2 inhibitors: a patent review (2014-2016). |
| Q98157749 | EZH2: a novel target for cancer treatment |
| Q57136305 | Emerging EZH2 Inhibitors and Their Application in Lymphoma |
| Q38435352 | Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets |
| Q52688790 | Enhancer of zeste homolog 2 (EZH2) inhibitors. |
| Q55433291 | Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia. |
| Q38537883 | Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions |
| Q26765402 | Epigenetic regulators and their impact on therapy in acute myeloid leukemia |
| Q38946185 | Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development |
| Q36682938 | Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia |
| Q38906678 | H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer |
| Q38832808 | HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia |
| Q37510247 | High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia. |
| Q39437966 | Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter |
| Q40789665 | Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model |
| Q64051997 | Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis |
| Q90751188 | Inhibition of Polycomb Repressive Complex 2 activity reduces trimethylation of H3K27 and affects development in Arabidopsis seedlings |
| Q38740496 | Inhibitors of Protein Methyltransferases and Demethylases. |
| Q47283050 | Injury Induces Endogenous Reprogramming and Dedifferentiation of Neuronal Progenitors to Multipotency |
| Q92703951 | Intersection of Epigenetic and Metabolic Regulation of Histone Modifications in Acute Myeloid Leukemia |
| Q37633585 | MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. |
| Q38747872 | Marked for death: targeting epigenetic changes in cancer |
| Q57721584 | MiCEE is a ncRNA-protein complex that mediates epigenetic silencing and nucleolar organization |
| Q36279590 | Multicellular Tumor Spheroids Combined with Mass Spectrometric Histone Analysis To Evaluate Epigenetic Drugs |
| Q38594002 | Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy |
| Q36169303 | Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer |
| Q39457118 | Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor. |
| Q88914220 | Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies |
| Q88585531 | Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target |
| Q41760786 | Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. |
| Q92429871 | PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation |
| Q90696382 | PTE, a novel module to target Polycomb Repressive Complex 1 to the human cyclin D2 (CCND2) oncogene |
| Q64964623 | Perturbing Enhancer Activity in Cancer Therapy. |
| Q42694670 | Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia |
| Q26801380 | Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications |
| Q57810481 | Polycomb complexes in normal and malignant hematopoiesis |
| Q35103527 | Polycomb genes, miRNA, and their deregulation in B-cell malignancies |
| Q26781745 | Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations |
| Q91173534 | Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia |
| Q36288331 | Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. |
| Q89575670 | Replicational Dilution of H3K27me3 in Mammalian Cells and the Role of Poised Promoters |
| Q58586793 | Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds |
| Q42321107 | Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. |
| Q93104286 | Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth |
| Q51020757 | Splicing of Ezh1 gets muscle out of stressful situations. |
| Q40968408 | Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors |
| Q28817780 | Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin |
| Q36445523 | Targeting EZH2 and PRC2 dependence as novel anticancer therapy |
| Q37204063 | Targeting EZH2 for cancer therapy: progress and perspective. |
| Q40014635 | Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment |
| Q89157968 | Targeting Transcription Factors for Cancer Treatment |
| Q26749450 | The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells |
| Q26784416 | The complexity of epigenetic diseases |
| Q38743320 | The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer |
| Q34516051 | The molecular mechanics of mixed lineage leukemia |
| Q53223003 | The polycomb group protein enhancer of zeste 2 is a novel therapeutic target for cervical cancer. |
| Q57826206 | The synthetic histone-binding regulator protein PcTF activates interferon genes in breast cancer cells |
| Q38729313 | Transcriptional Selectivity of Epigenetic Therapy in Cancer. |
| Q56886543 | ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer |
| Q88121008 | [Histone modification aberrations in acute myeloid leukemia and the target therapy development in clinical settings] |
| Q51502591 | miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells. |
Search more.